Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1977-1985

  Tesch, Greg ^a,b   Sourris, Karly C ^b,c   Summers, Shaun A ^a,b   McCarthy, Domenica ^d   Ward, Micheal S ^d   Borg, Danielle J ^d   Gallo, Linda A ^d   Fotheringham, Amelia K ^d   Pettit, Allison R ^d   Yap, Felicia Y T ^c   Harcourt, Brooke E ^c,d   Tan, Adeline L Y ^c   Kausman, Joshua Y ^b   Nikolic Paterson, David ^a,b   Kitching, Arthur R ^a,b   Forbes, Josephine M ^c,d,e  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Diabetes; Inflammation; Kidney; Macrophages

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CALGRANULIN A; CALGRANULIN B; CD19 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; GLYCOPROTEIN P 15095; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; ALPHA SMOOTH MUSCLE ACTIN; ARGINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN S 100; SIALOADHESIN; STREPTOZOCIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL DIABETIC NEUROPATHY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GLOMERULOSCLEROSIS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; KIDNEY STRUCTURE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUBULO INTERSTITIAL INJURY; URINARY EXCRETION; WILD TYPE; ANIMAL TISSUE; BONE MARROW DERIVED MACROPHAGE; CHIMERA; GENE DELETION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; GENETICS; KIDNEY; METABOLISM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; KIDNEY; MACROPHAGES; MALE; MICE; RECEPTORS, IMMUNOLOGIC;

EID: 84905577201     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3291-z     Document Type: Article

References (27)

1. Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93:137-188
2. US Renal Data System (2013) USRDS 2008 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
3. 2010 Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073-2081
4. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH (2007) Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50:471-480
5. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73-80
6. Navarro JF, Mora C, Gomez M, Muros M, Lopez-Aguilar C, Garcia J (2008) Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. Nephrol Dial Transplant 23:919-926
7. Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433-442
8. Inagi R, Yamamoto Y, Nangaku M, et al. (2006) A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55:356-366
9. Sourris KC, Morley AL, Koitka A, et al. (2010) Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53:2442-2451
10. Tan AL, Sourris KC, Harcourt BE, et al. (2010) Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 298:F763-F770
11. Wendt TM, Tanji N, Guo J, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137
12. Bierhaus A, Humpert PM, Morcos M, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83:876-886
13. Bierhaus A, Schiekofer S, Schwaninger M, et al. (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50:2792-2808
14. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
15. Morris-Rosenfeld S, Blessing E, Preusch MR, et al. (2011) Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. Eur J Clin Invest 41:1164-1171
16. Liliensiek B, Weigand MA, Bierhaus A, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113:1641-1650
17. Forbes JM, Thallas V, Thomas MC, et al. (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764
18. Coughlan MT, Thallas-Bonke V, Pete J, et al. (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148:886-895
19. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. (2008) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57:460-469
20. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65:116-128
21. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH (2005) Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16:1711-1722
22. Tesch GH (2010) Macrophages and diabetic nephropathy. Semin Nephrol 30:290-301
23. Lim AK, Ma FY, Nikolic-Paterson DJ, Kitching AR, Thomas MC, Tesch GH (2010) Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury. Diabetologia 53:1772-1782
24. Zheng F, Cornacchia F, Schulman I, et al. (2004) Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 53:2420-2427
25. Kokkola R, Andersson A, Mullins G, et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9
26. Lewis EJ, Greene T, Spitalewiz S, et al. (2012) Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23:131-136
27. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH (2009) Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52:1669-1679